Industrial strength for Sanford-Burnham

Almost two years after its previous CEO, John Reed, left to run Roche's Pharma Research and Early Development unit, Sanford-Burnham has turned to pharma for a successor. Incoming CEO Perry Nisen hopes to use what he learned in his 10 yearsat GlaxoSmithKline plc to foster partnerships and generate clinical candidates that can meet industry standards.

Nisen was SVP of science and innovation at GSK and will take the helm at the Sanford-Burnham Medical Research Institute on Sept. 15. President and interim CEO Kristiina Vuori will remain president. Reed, who joined Roche in January 2013, left the institute after 11 years as CEO...